#ACR21 plenary#1424. JUNIPERA study for Secukinumab for ERA, JPsA ⭐️Time to disease flare longer in SEC vs PBO ⭐️Sustained improvement up to wk 104 ▶️Rapid decrease of JADAS-27 in initial open-label portion of study https://t.co/m5bl9Ho163 @Rheumnow https://t.co/wnEdxeYfjh